{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:29:56Z","timestamp":1780457396121,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s41669-021-00303-5","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T22:10:33Z","timestamp":1633385433000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study"],"prefix":"10.1007","volume":"6","author":[{"given":"Pedro","family":"Labisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6478-8456","authenticated-orcid":false,"given":"Valeska","family":"Andreozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Vandewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Canh\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Beitia Ortiz de Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,3]]},"reference":[{"issue":"1","key":"303_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"303_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"1","key":"303_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"303_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochm\u00fcller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643\u201353.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"303_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mus.26441","volume":"59","author":"AM Connolly","year":"2019","unstructured":"Connolly AM, Zaidman CM, Golumbek PT, Cradock MM, Flanigan KM, Kuntz NL, et al. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle Nerve. 2019;59(6):650\u20137.","journal-title":"Muscle Nerve"},{"key":"303_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"303_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10198-016-0782-5","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, Kodra Y, Armeni P, De Santis M, Lopez-Bastida J, Linertova R, et al. Social\/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ HEPAC. 2016;17(Suppl 1):19\u201329.","journal-title":"Eur J Health Econ HEPAC"},{"issue":"6","key":"303_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336.","journal-title":"Neurology"},{"issue":"5","key":"303_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"303_CR10","unstructured":"Instituto Nacional de Estat\u00edstica 2020. 2020. https:\/\/www.ine.pt\/xportal\/xmain?xpgid=ine_main&xpid=INE."},{"key":"303_CR11","unstructured":"Portaria no. 254\/2018 de 7 de setembro. Di\u00e1rio da Rep\u00fablica, 1.\u00aa s\u00e9rie\u2014No. 173\u20147 de setembro de 2018. 2018."},{"key":"303_CR12","unstructured":"Portaria no. 207\/2017 de 11 de julho. Di\u00e1rio da Rep\u00fablica, 1.\u00aa s\u00e9rie\u2014No. 132\u201411 de julho de 2017. 2017."},{"key":"303_CR13","unstructured":"IP ACdSdS. Termos de Refer\u00eancia para contratualiza\u00e7\u00e3o de cuidados de sa\u00fade no SNS para 2019. 2019."},{"key":"303_CR14","unstructured":"Infomed. Base de dados de medicamentos. 2021. http:\/\/app7.infarmed.pt\/infomed\/pesquisa.php."},{"key":"303_CR15","unstructured":"Base.gov. Contratos p\u00fablicos online. 2021. http:\/\/www.base.gov.pt\/Base\/pt\/Homepage."},{"issue":"4","key":"303_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00019053-200826040-00001","volume":"26","author":"MA Koopmanschap","year":"2008","unstructured":"Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26(4):269\u201380.","journal-title":"Pharmacoeconomics"},{"key":"303_CR17","unstructured":"Zweifel P, Breyer F. Health Economics. Oxford: Oxford University Press I; 1997."},{"key":"303_CR18","unstructured":"INdEI. Ganho m\u00e9dio mensal (\u20ac) por Localiza\u00e7\u00e3o geogr\u00e1fica (NUTS\u20142013), Sexo e Grupo et\u00e1rio; Anual 2019. 2019. https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0006914&contexto=bd&selTab=tab2&xlang=pt."},{"key":"303_CR19","unstructured":"PP. Guia Fiscal 2017\u2014Seguran\u00e7a Social. 2017. https:\/\/www.pwc.pt\/pt\/pwcinforfisco\/guia-fiscal\/2017\/seguranca-social.html."},{"key":"303_CR20","unstructured":"INdEI. Dura\u00e7\u00e3o semanal efectiva de trabalho (S\u00e9rie 2011\u2014h) da popula\u00e7\u00e3o empregada por Local de resid\u00eancia (NUTS\u20142013), Sexo e Sector de actividade econ\u00f3mica (CAE Rev. 3); Anual 2019. 2019. https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0006181&contexto=bd&selTab=tab2."},{"issue":"5","key":"303_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00246-018-1881-0","volume":"39","author":"TD da Silva","year":"2018","unstructured":"da Silva TD, Massetti T, Crocetta TB, de Mello Monteiro CB, Carll A, Vanderlei LCM, et al. Heart rate variability and cardiopulmonary dysfunction in patients with duchenne muscular dystrophy: a systematic review. Pediatr Cardiol. 2018;39(5):869\u201383.","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"303_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/pri.1605","volume":"20","author":"EV de Carvalho","year":"2015","unstructured":"de Carvalho EV, Hukuda ME, Escorcio R, Voos MC, Caromano FA. Development and reliability of the functional evaluation scale for Duchenne Muscular Dystrophy, Gait domain: a pilot study. Physiother Res Int. 2015;20(3):135\u201346.","journal-title":"Physiother Res Int"},{"issue":"4","key":"303_CR23","doi-asserted-by":"publisher","first-page":"e001338","DOI":"10.1161\/JAHA.114.001338","volume":"4","author":"A Tandon","year":"2015","unstructured":"Tandon A, Villa CR, Hor KN, Jefferies JL, Gao Z, Towbin JA, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and Is associated with age and steroid treatment duration in Duchenne Muscular Dystrophy. J Am Heart Assoc. 2015;4(4):e001338.","journal-title":"J Am Heart Assoc"},{"key":"303_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1590\/S0004-282X2010000500002","volume":"68","author":"SLS Parreira","year":"2010","unstructured":"Parreira SLS, Resende MBD, Zanoteli E, Carvalho MS, Marie SK, Reed UC. Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy. Arq Neuropsiquiatr. 2010;68:683\u20138.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"303_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5535\/arm.2012.36.1.22","volume":"36","author":"I-Y Jung","year":"2012","unstructured":"Jung I-Y, Chae JH, Park SK, Kim JH, Kim JY, Kim SJ, et al. The correlation analysis of functional factors and age with duchenne muscular dystrophy. Ann Rehabil Med. 2012;36(1):22\u201332.","journal-title":"Ann Rehabil Med"},{"issue":"4","key":"303_CR26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00415-012-6733-x","volume":"260","author":"A Fischmann","year":"2013","unstructured":"Fischmann A, Hafner P, Gloor M, Schmid M, Klein A, Pohlman U, et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol. 2013;260(4):969\u201374.","journal-title":"J Neurol"},{"issue":"11","key":"303_CR27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","volume":"20","author":"E Mazzone","year":"2010","unstructured":"Mazzone E, Martinelli D, Berardinelli A, Messina S, D\u2019Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20(11):712\u20136.","journal-title":"Neuromuscul Disord"},{"key":"303_CR28","doi-asserted-by":"publisher","DOI":"10.1201\/9781315370279","volume-title":"Generalized additive models: an introduction with R","author":"SN Wood","year":"2017","unstructured":"Wood SN. Generalized additive models: an introduction with R. Boca Raton: CRC Press; 2017."},{"key":"303_CR29","unstructured":"R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019."},{"key":"303_CR30","doi-asserted-by":"crossref","unstructured":"Garrido C, Palavra F, Cardoso M, Sousa A, Rocha R, Alves D, et al. Duchenne Muscular Dystrophy\u2013Clinical: P. 16Epidemiology, clinical and genetic features of Duchenne disease in Portugal: a multicentre retrospective study. Neuromuscul Disord. 2018;28:S36.","DOI":"10.1016\/j.nmd.2018.06.045"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-021-00303-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T17:43:10Z","timestamp":1645551790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-021-00303-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s41669-021-00303-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,3]]},"assertion":[{"value":"5 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PL, VA, MM, SM, RA, JA, BV, and JF are employees of Exigo Consultores. Exigo Consultores provides consulting services to PTC Therapeutics under a fee-for-services contract. KB, HC, and IBOZ are employees of PTC Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was funded by PTC Therapeutics. Authors affiliated with Exigo are employees of an independent consulting firm and maintained independent scientific control over the study, including data analysis and interpretation of final results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"COIDUCH was developed following a direct request by the National Authority of Medicines and Health Products (INFARMED) after the reimbursement decision for Translarna\u00ae in Portugal. Following this request, the study protocol was developed and sent to INFARMED, which validated it. Note that, since 2014, the Ethics Committee for Clinical Investigation (CEIC) has been working with INFARMED to approve nationwide studies whenever a local ethics committee for health (CES) has not been designated for the purpose. This was the case with COIDUCH, as it did not involve any hospital (where CES are often located). Ethical principles and good clinical research practices guided the execution of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Prior written informed consent was obtained from participants. The anonymity of the participants was guaranteed. All personal data were managed according to the General Data Protection Regulation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable as the manuscript does not contain any personal data related to an identified or identifiable participant.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"An Excel database was developed in which to register the original data from the questionnaire, and the software R was used to analyze the data. All aggregate data generated or analysed are included in this published article. No individual data are available to protect the anonymity of individual patients.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PL and MM designed the study, collected the data, and drafted the manuscript. VA designed the study, analysed the data, and drafted the manuscript. SM and JA collected the data. JF and BV designed the study and contributed to the interpretation of the data. KB, HC, and IBOZ supported the planning phase of the interviews. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}